# Vertex Acquires Crinetics Pharmaceuticals for $10 Billion in Largest Deal in Vertex History

> ma · REPORTED · 2026-07-06

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, gaining the commercial rare-disease drug Palsonify for acromegaly and a pipeline candidate for congenital adrenal hyperplasia, the largest acquisition in Vertex's history as it diversifies beyond cystic fibrosis. Crinetics shares rose over 100% in after-hours trading on the news.

About Vertex Pharmaceuticals: Crinetics Pharmaceuticals is a rare endocrine disease company whose lead commercial product Palsonify treats acromegaly, with additional pipeline assets targeting congenital adrenal hyperplasia and other hormonal disorders.

- Company: Vertex Pharmaceuticals
- Sector: biotech
- Primary source: https://www.statnews.com/2026/07/06/vertex-acquires-crinetics-pharmaceuticals/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.